

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO.		APPLICATION NO.	
				4821-411		To Be Assigned	
				APPLICANT			
				J. YOUNG et al.			
FILING DATE				GROUP			
January 29, 2001				To Be Assigned			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	CLASS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
					SS	SS	IF APPROPRIATE
	AA	6,127,363	10/2000	Doherty et al.	514	220	
	AB	5,795,880	08/1998	Svec et al.	514	169	
	AC	5,780,051	07/1998	Eswara et al.	424	449	
	AD	5,733,566	03/1998	Lewis	424	426	
	AE	5,719,283	02/1998	Bell et al.	544	262	
	AF	5,674,553	10/1997	Shinoda et al.	427	68	
	AG	5,639,476	06/1997	Oshlack et al.	424	468	
	AH	5,591,767	01/1997	Mohr et al.	514	413	
	AI	5,552,429	09/1996	Wong et al.	514	415	
	AJ	5,459,164	10/1995	Vargas	514	646	
	AK	5,436,272	07/1995	Scheinbaum	514	646	
	AL	5,354,556	10/1994	Sparks et al.	424	419	
	AM	5,250,534	10/1993	Bell et al.	514	258	
	AN	5,120,548	06/1992	McClelland et al.	424	473	
	AO	5,104,899	04/1992	Young et al.	514	646	
	AP	5,073,543	12/1991	Marshall et al.	514	21	
	AQ	5,068,440	11/1991	Jeffery et al.	564	442	
	AR	5,059,595	10/1991	Le Grazie	424	468	
	AS	4,988,814	01/1991	Abou-Gharbia et al.	544	295	
	AT	4,939,175	07/1990	Ukai et al.	514	646	
	AU	4,929,629	05/1990	Jeffery	514	646	
	AV	4,871,774	10/1989	Rees	514	646	
	AW	4,816,488	03/1989	Rees	514	646	
	AX	4,814,352	03/1989	Jeffery et al.	514	646	
	AY	4,806,570	02/1989	Jeffery et al.	514	646	
	AZ	4,746,680	05/1988	Jeffery et al.	514	646	
	BA	4,552,828	11/1985	Toya et al.	430	217	
	BB	4,522,828	06/1985	Jeffery et al.	514	646	
	BC	4,008,719	02/1977	Theeuwes et al.	128	260	
	BD	3,960,891	06/1976	Malen et al.	260	327	
	BE	3,916,899	11/1975	Theeuwes et al.	128	260	
	BF	3,845,770	11/1974	Theeuwes et al.	128	260	
	BG	3,598,123	08/1971	Zaffaroni	128	268	

	BH	3,536,809	10/1970	Applezweig	424	28	
	BI	3,471,515	10/1969	Troxler et al.	260	326.15	
	BJ	3,155,670	11/1964	Janssen et al.	260	294	
	BK	3,155,669	11/1964	Janssen et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
			E		SS	LASS	YES
							NO
	BL	WO 99/33450	07/1999	PCT (in English)			
	BM	WO 98/13034	04/1998	PCT (in English)			
	BN	WO 98/13033	04/1998	PCT (in English)			
	BO	WO 98/11884	03/1998	PCT (in English)			
	BP	WO 98/06722	02/1998	PCT			X _(aba)
	BQ	EP 0 781 561 A1	07/1997	EPO (in English)			
	BR	WO 97/20810	06/1997	PCT (in English)			
	BS	WO 97/03675	02/1997	PCT (in English)			
	BT	WO 95/21615	08/1995	PCT (in English)			
	BU	WO 95/20949	08/1995	PCT (in English)			
	BV	WO 94/28902	12/1994	PCT (in English)			
	BW	WO 94/00114	01/1994	PCT (in English)			
	BX	WO 94/00047	01/1994	PCT (in English)			
	BY	WO 90/06110	06/1990	PCT (in English)			
	BZ	WO 88/06444	09/1988	PCT (in English)			
	CA	DE 32 12 682 A1	10/1982	Germany			X _(aba)
	CB	GB 2098602 A	11/1982	United Kingdom			
	CC	EP 0 035 597	9/1981	Europe			
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
—	CD	Baldessarini et al., <i>Life Sciences</i> 39: 1765-1777, (1986).					
—	CE	Buckett et al., "BTS 54 524-An Approach to Rapidly Acting Antidepressant," <i>New Concepts in Depression</i> 2: 167-172 (1988).					
—	CF	Buckett et al., "The Pharmacology of Sibutramine Hydrochloride (BTS 54 524), A New Antidepressant which induces Rapid Noradrenergic Down-Regulation", <i>Prog. Neuro-Psychopharmacol. & Biol. Psychiat.</i> 12: 575-584 (1988).					
	CG	Buckett et al., "Sibutramine Hydrochloride," <i>Drugs of the Future</i> 13(8): 736-738 (1988).					
—	CH	Butler, D., <i>Facile Cycloalkylation of Arylacetonitriles in Dimethyl Sulfoxide</i> , <i>J. Org. Chem.</i> , 36:1308-1309 (1971)					
—	CI	Canonne, P., et al., <i>Effet du Benzene Dans la Reaction de Grignard sur les Nitriles</i> , <i>Tetrahedron Lett.</i> , 21:155-58 (1980)					
—	CJ	Carstensen, J., <i>Drug Stability: Principles & Practice</i> , 2d. Ed., pp. 379-80, Marcel Dekker, NY, NY, (1995).					
—	CK	Castello, R.A., et al., <i>Discoloration of Tablets Containing Amines and Lactose</i> , <i>Pharm. Sci.</i> 51(2):106-108 (1962)					
—	CL	Cheetham, S.C., et al., [³ H]Paroxetine Binding in Rat Frontal Cortex Strongly Correlates with [³ H]5-HT Uptake: Effect of Administration of Various Antidepressant Treatments, <i>Neuropharmacology</i> (1993), 32(8), 737-743					
—	CM	Cliffe et al., (S)-N-tert-Butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: A Selective Antagonist at Presynaptic and Postsynaptic 5-HT _{1A} Receptors, <i>Med. Chem.</i> , 36:1509-1510 (1993)					
—	CN	<i>Diagnostic and Statistical Manual of Mental Disorders</i> , Fourth Ed., American Psychiatric Association, (1997).					
—	CO	<i>Diagnostic and Statistical Manual of Mental Disorders</i> , 3rd Ed., American Psychiatric Association (1981).					
—	CP	Dreshfield et al., <i>Enhancement of Fluoxetine-Dependent Increase of Extracellular Serotonin (5-HT) Levels by (-)-Pindolol, an Antagonist at 5-HT_{1A} Receptors</i> , <i>Neurochem. Res.</i> , 21(5):557-562 (1996)					
—	CQ	Eliel, E.L., <i>Stereochemistry of Carbon Compounds</i> (McGraw-Hill, NY, 1962).					

1	CR	Evans et al., "Prevalence of Alzheimer's Disease in a Community Population of Older Persons," <i>J.A.M.A.</i> 262 : 2551-2556 (1989).
1	CS	Fuentes, J. et al., "Comparison of the apparent anti-depressant activity of (-) and (+) tranylpromine in an animal model", <i>Chemical Abstracts</i> , 85 : 7, page 31, No. 40768t (1976).
1	CT	Goodman & Gilman, <i>The Pharmacological Basis of Therapeutics</i> , 362-373, 404 (9 th ed. McGraw-Hill, 1996)
1	CU	Gray et al., <i>The Involvement of the Opioidergic System in the Antinociceptive Mechanism of Action of Antidepressant Compounds</i> , <i>BR.J. Pharmacol.</i> , Vol. 124, No. 4, (1998) pp 669-674
1	CV	<i>Handbook of Pharmaceutical Excipients</i> , 2 nd ed., Wade and Willer eds., pp. 257-259 (1994)
1	CW	Heal et al., <i>A Comparison of the Effects on Central 5-HT Function of Sibutramine Hydrochloride and Other Weight-Modifying Agents</i> , <i>BR.J. Pharmacol.</i> (1998), 125(2), 301-308
1	CX	Hillyer et al., (S)-5-Fluoro-8-hydroxy-2-(dipropylamino)tetralix: A Putative 5-HT _{1A} Receptor Antagonist, <i>J. Med. Chem.</i> , 33:1541-44 (1990)
1	CY	<i>J. Med. Chem.</i> , Vol. 36, No. 17, 2540 (1993)
1	CZ	<i>Introduction to Pharmaceutical Dosage Forms</i> , 4th ed., Lea & Febiger, Philadelphia (1985).
1	DA	Jacques et al., "Enantiomers, Racemates and Resolutions," (Wiley-Interscience, NY, 1981).
1	DB	Jamali et al., <i>Journal of Pharmaceutical Sciences</i> , 78 : 9: 695-715 (1989)
1	DC	Jeffery et al., <i>Synthesis of Sibutramine, A Novel Cyclobutylalkylamine Useful in the Treatment of Obesity, and its Major Human Metabolites</i> , <i>J. Chem. Soc. Perkin. Trans. 1</i> , 2583-2589 (1996)
1	DD	King et al., "Clinical Pharmacology of Sibutramine Hydrochloride (BTS 54524) A New Antidepressant, in Healthy Volunteers," <i>Clinical Pharmacol.</i> 26 : 607-611 (1989).
1	DE	Kula et al., "Effects of N-Substituted Phenyltetrahydropyridines on Cerebral High-Affinity Synaptosomal Uptake of Dopamine and Other Monoamines in Several Mammalian Species," <i>Life Sciences</i> 34 (26): 2567-2575, (1984).
1	DF	Luscombe et al., <i>The Contribution of Metabolites to the Rapid and Potent Down-Regulation of Rat Cortical β-Adrenoceptors by the Putative Antidepressant Sibutramine Hydrochloride</i> , <i>Neuropharmacology</i> , Vol. 28, No. 2, (1989) pp 129-134
1	DG	<i>The Merck Manual of Diagnosis and Therapy</i> , 17th Ed., Merck & Co., Inc., Whitehouse Station, NJ, (1999).
1	DH	Middlemiss et al., <i>Centrally Active 5-HT Receptor Agonists and Antagonists</i> , <i>Neurosci. and Biobehv. Rev.</i> , 16:75-82 (1992)
1	DI	Moreau et al., <i>Behavioral Profile of the 5-HT_{1A} Receptor Antagonist (S)-UH-301 in Rodents and Monkeys</i> , <i>Brain Res. Bull.</i> , 29:901-04 (1992)
1	DJ	Nakada et al., <i>An Enantioconvergent Route to (-)-Kainic Acid</i> , <i>Tetrahedron Lett.</i> , 38:857-860 (1997)
	DK	<i>Physician's Desk Reference</i> ® 473-475 (53 rd ed., 1999)
	DL	<i>Physician's Desk Reference</i> ® 475-476 (53 rd ed., 1999)
	DM	<i>Physician's Desk Reference</i> ® 764-766 (53 rd ed., 1999)
	DN	<i>Physician's Desk Reference</i> ® 823-825 (53 rd ed., 1999)
	DO	<i>Physician's Desk Reference</i> ® 978-979 (53 rd ed., 1999)
	DP	<i>Physician's Desk Reference</i> ® 1054-1056 (53 rd ed., 1999)
	DQ	<i>Physician's Desk Reference</i> ® 1332-1334 (53 rd ed., 1999)
	DR	<i>Physician's Desk Reference</i> ® 1369-1370 (53 rd ed., 1999)
	DS	<i>Physician's Desk Reference</i> ® 1432-1436 (53 rd ed., 1999)
	DT	<i>Physician's Desk Reference</i> ® 1494-1498 (53 rd ed., 1999)
	DU	<i>Physician's Desk Reference</i> ® 1641-1645 (53 rd ed., 1999)
	DV	<i>Physician's Desk Reference</i> ® 2004-2009 (53 rd ed., 1999)
	DW	<i>Physician's Desk Reference</i> ® 2075-2078 (53 rd ed., 1999)
	DX	<i>Physician's Desk Reference</i> ® 2190-2192 (53 rd ed., 1999)
	DY	<i>Physician's Desk Reference</i> ® 2367-2368 (53 rd ed., 1999)
	DZ	<i>Physician's Desk Reference</i> ® 2396-2399 (53 rd ed., 1999)
	EA	<i>Physician's Desk Reference</i> ® 2490-2493 (53 rd ed., 1999)
	EB	<i>Physician's Desk Reference</i> ® 2516-2521 (53 rd ed., 1999)
	EC	<i>Physician's Desk Reference</i> ® 2688-2691 (53 rd ed., 1999)
	ED	<i>Physician's Desk Reference</i> ® 2701-2704 (53 rd ed., 1999)
	EE	<i>Physician's Desk Reference</i> ® 2720-2726 (53 rd ed., 1999)
	EF	<i>Physician's Desk Reference</i> ® 2735-2736 (53 rd ed., 1999)

	EG	Physician's Desk Reference® 2886-2888 (53 rd ed., 1999)
	EH	Physician's Desk Reference® 2908-2910 (53 rd ed., 1999)
	EI	Physician's Desk Reference® 3092-3094 (53 rd ed., 1999)
	EJ	Physician's Desk Reference® 3101-3104 (53 rd ed., 1999)
	EK	Physician's Desk Reference® 3224-3225 (53 rd ed., 1999)
	EL	Physician's Desk Reference® 3267-3272 (53 rd ed., 1999)
	EM	Physician's Desk Reference® 3307-3309 (53 rd ed., 1999)
	EN	Physician's Desk Reference® 3383-3384 (53 rd ed., 1999)
	EO	Physician's Desk Reference® 2520 (52 nd ed., 1998)
	EP	Physician's Desk Reference® 2958 (52 nd ed., 1998)
—	EQ	Remington's: The Practice of The Science and Pharmacy, 19 th ed., Gennaro, ed., p. 1625 (1995)
—	ER	Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton PA (1990).
—	ES	Remington's Pharmaceutical Sciences, 16th ed., Mack Publishing, Easton PA (1980).
—	ET	Stock, M.J., Sibutramine: A Review of the Pharmacology of a Novel Anti-Obesity Agent, Int'l J. Obesity, 21(Supp. 1):S25-S29 (1997)
—	EU	U.S. Pharmacopia (USP) SP (XXI)/NF (XVI)
—	EV	Wilen et al., Tetrahedron, 2725-36 33(21) (1977).
—	EW	Wilen, S.H., Tables of Resolving Agents and Optical Resolutions 268 (E.L. Eliel ed., Univ. of Notre Dame Press, Notre Dame, IN, 1972).
EXAMINER		DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		